Risk factors for rapid axial length elongation with low concentration atropine for myopia control

Aicun Fu1, Fiona Stapleton2, Li Wei1

  • 1The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe road, Zhengzhou, 450000, China.

Scientific Reports
|June 4, 2021
PubMed

Insights

Younger children using lower concentration 0.01% atropine eye drops may experience rapid axial length elongation. This myopia progression is linked to shorter baseline axial length and smaller pupil diameter changes over 12 months.

Area of Science:

  • Ophthalmology
  • Pediatric Ophthalmology
  • Myopia Control

Background:

  • Myopia is a growing global health concern, particularly in children.
  • Effective myopia control strategies are crucial to prevent high myopia and associated ocular pathologies.
  • Low-dose atropine eye drops are a recognized treatment for slowing myopia progression.

Purpose of the Study:

  • To identify risk factors associated with rapid axial length (AL) elongation in myopic children undergoing atropine treatment.
  • To compare the effects of 0.01% and 0.02% atropine concentrations on myopia progression.
  • To analyze the relationship between baseline characteristics and AL changes over a 12-month period.

Main Methods:

  • A randomized study involving 328 myopic children using either 0.01% or 0.02% atropine.
  • Collection of baseline and 1-year data including age, BMI, refractive error (SER), anterior chamber depth (ACD), and axial length (AL).
  • Statistical analyses (univariate and multivariate logistic regression) to determine predictors of rapid AL elongation (>0.36 mm/year).

Main Results:

  • Rapid AL elongation was associated with younger age at baseline (P < 0.0001).
  • Use of 0.01% atropine was linked to increased risk of rapid AL elongation (P = 0.04).
  • Shorter baseline AL (P = 0.03) and smaller changes in pupil diameter (P = 0.04) were also significant predictors.

Conclusions:

  • Younger children with shorter baseline axial length are at higher risk for rapid AL elongation.
  • The lower concentration of 0.01% atropine may be less effective in preventing rapid axial length growth compared to higher concentrations.
  • Smaller changes in pupil diameter during treatment may indicate a higher risk of myopia progression.

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
779
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
906
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.0K
Focusing of Light in the Eye01:16

Focusing of Light in the Eye

Light rays enter the eye through the cornea, a transparent dome-shaped tissue that is the eye's outermost layer. The cornea bends or refracts, light rays traveling to the pupil. The shape of the cornea determines how much of the light is bent and whether the image will be focused correctly on the retina at the back of the eye. Once the light has passed through both refraction layers, it converges into a single focal point onto a small area. This is where photoreceptors start transforming...
3.7K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.9K
Accessory Structures of the Eye01:17

Accessory Structures of the Eye

Optical perception, or vision, is an extraordinary sense dependent on converting light signals received via the ocular organs. These organs, known as eyes, are securely positioned within the bony cavities of the skull, called orbits. The orbits serve a dual purpose: a protective shield for the ocular globes and a stable attachment point for the soft ocular tissues. The eye's external protective mechanisms include the eyelids, which are edged with lashes that act as a barrier against foreign...
2.4K